NRx Pharmaceuticals (NASDAQ:NRXP) is a clinical-stage pharmaceutical company. It focuses on developing treatments for central nervous system disorders, including suicidal depression and PTSD. The company's financial health shows some challenges, with a negative price-to-earnings (P/E) ratio of -4.32, which indicates it is not currently profitable over the last year.
On May 18, 2026, NRx Pharmaceuticals announced its quarterly earnings. The company reported an earnings per share (EPS) of -$0.04. This figure surpassed the analyst consensus estimate of -$0.05. This result also shows a significant improvement from the loss of $0.34 per share reported in the same quarter of the previous year.
However, the company's revenue for the quarter was $1.07 million. This amount fell short of the Zacks Consensus Estimate by over 91%, which was projected at $19.43 million. While a miss, this revenue is a notable increase from the zero revenues recorded in the same quarter a year ago.
Looking ahead, NRx Pharmaceuticals anticipates a decision from the FDA in the third quarter of 2026 for its Preservative-Free Ketamine. The company has already started commercial manufacturing of one million doses per month in preparation. The facility recently passed an FDA inspection, which is a positive step for a potential launch.
The company also received FDA clearance to start a clinical trial for its drug NRX-101. This trial will test the drug's effectiveness in patients with depression and suicidality. Following these developments, NRx Pharmaceuticals' shares saw an increase, as highlighted by Benzinga, showing positive investor reaction to the company's pipeline progress.
